Table 3.

All Grade Adverse Events Regardless of Attribution at Baseline and Post-Baseline (CTCAE version 5.0)

		Baseline Grade		Post-Baseline Grade
		1 (n)	2 (n)	1 (n)	2 (n)	3 (n)	4 (n)	5 (n)
Category		1	.	.	.	.	.	.
Ear and labyrinth disorders	Tinnitus
Gastrointestinal disorders	Nausea	3	.	1	.	.	.	.
General disorders and administration site conditions	Death NOS	.	.	.	.	.	.	7
	Disease progression	.	.	.	.	.	.	1
	Fatigue	8	3	2	.	.	.	.
	Gait disturbance	1	.	.	.	.	.	.
	General disorders and administration site conditions— Other, specify	1	1	.	.	.	.	.
Infections and infestations	Infections and infestations—Other, specify	.	.	.	1	.	.	.
Metabolism and nutrition disorders	Anorexia	2	.	.	.	.	.	.
Musculoskeletal and connective tissue disorders	Arthralgia	1	.	.	.	.	.	.
	Back pain	2	.	.	.	.	.	.
	Generalized muscle weakness	.	2	.	1	.	.	.
	Muscle weakness lower limb	.	.	1	.	.	.	.
	Muscle weakness upper limb	1	.	.	.	.	.	.
Nervous system disorders	Ataxia	1	.	1	.	.	.	.
	Cognitive disturbance	1	.	.	.	.	.	.
	Concentration impairment	1	.	.	.	.	.	.
	Dysarthria	1	2	.	.	.	.	.
	Dysphasia	1	.	.	.	.	.	.
	Edema cerebral	.	2	1	.	.	1	.
	Headache	7	.	.	.	1	.	.
	Hydrocephalus	.	.	.	.	.	1	.
	Memory impairment	1	.	.	.	.	.	.
	Muscle weakness right-sided	.	2	.	.	.	.	.
	Seizure	6	3	.	.	.	1	.
Psychiatric disorders	Anxiety	1	.	.	.	.	.	.
	Confusion	1	.	.	.	.	.	.
	Depression	1	.	.	.	.	.	.
Maximum grade of any toxicity		8	6	2	1	0	0	8